Congratulations on Zhejiang Cheng Yi Pharmaceutical Ltd successfully passed the first globle GMP joint audit for Ribavirin, Azathioprine and 6-Mercaptopurine APIs, which raised by Australia TGA, US FDA, EU EMEA and Singapore HSA on its main products, quality system and plant facilities.

EMEA	FDA	TGA

Since its foundation in 1966, Cheng Yi Pharmaceutical has established itself as a reliable manufacturer and supplier of APIs and pharmaceutical intermediates, as well as a contract manufacturing partner to the pharmaceutical industry. Our manufacturing facilities were first audited by TGA in 1998, and have since been regularly inspected and consistently approved by other world regulatory authorities. In particular, we are proud of the success in the first global joint audit of our facilities by FDA, EMEA and TGA in 2010. At Cheng Yi pharmaceutical, we are committed to manufacturing excellence and strict compliance with cGMP requirements.